

If you are unable to see this message, [click here to view](#).



## News from the Association of American Cancer Institutes

June 2018

### IN THIS ISSUE

#### HEADLINES

Theodorescu Appointed Director at Cedars-Sinai

Regular Registration Ends June 11 for 10th Annual AACI CRI Meeting

AACI/CCAF Annual Meeting to Feature Cancer Health Economics Panel

CRI Webinar - Satellite Locations

AACI Contributes to Report on Clinical Trial Enrollment

#### NEWS FROM THE CENTERS

Awards & Honors

Grants & Gifts

Leadership Transitions

Research Highlights

Other News

#### JOB OPPORTUNITIES

#### MEETING ANNOUNCEMENTS

### Headlines

#### Theodorescu Appointed Director at Cedars-Sinai

Cancer clinician and scientist **Dan Theodorescu, MD, PhD** has been named director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, in Los Angeles. He has served since 2010 as director of the University of Colorado Cancer Center and will assume his new post July 1.



Dr. Theodorescu, a translational cancer researcher and leading expert in bladder cancer, will bring a compelling vision to Cedars-Sinai, leading what he sees as three revolutions shaping modern cancer care: using precision medicine strategies to personalize treatments; tapping "big data" to solve difficult research and treatment questions; and employing population health ideas to improve the lot of entire populations while reducing health inequities among groups. [more...](#)

#### Regular Registration Ends June 11 for 10th Annual AACI CRI Meeting



The 10th Annual AACI Clinical Research Initiative (CRI) Meeting will be held July 11-12, in Chicago, IL, at the Loews Chicago O'Hare Hotel. This year's meeting, with a theme of "Leveraging Change to Advance Cures for Cancer Patients", will feature a session on the challenges for physicians, advance practice providers and clinical care teams of integrating clinical research with clinical care.

Registration is ongoing, with more than 300 participants from 68 cancer centers currently registered. Regular registration rates will end on June 11. More information on the meeting, including the program and electronic registration, is available on the CRI meeting [website](#). [more...](#)

#### AACI/CCAF Annual Meeting to Feature Cancer Health Economics Panel

Four panelists will offer their perspectives on cancer health economics at the AACI/CCAF Annual Meeting, to be held September 30 - October 2, in Chicago. Annual Meeting Program Committee Chair and director of the University of Hawai'i Cancer Center, Randall F. Holcombe, MD, MBA, will moderate the panel on October 1. Panelists include Rena M. Conti, PhD, University of Chicago; Stuart Peacock, PhD, BC Cancer; and Robin Yabroff, PhD, MBA, American Cancer Society.



Information on the annual meeting, including the program and electronic registration, is available on the [AACI website](#). [more...](#)

#### CRI Webinar - Satellite Locations

AACI's Clinical Research Initiative (CRI) will present its webinar, "Satellite Locations," on Wednesday, June 6, at 1:30 pm EST. The webinar will be hosted by AACI and presented by Laurin Priddy, clinical research manager at Simmons Comprehensive Cancer Center, UT

### MISSION

The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.

### ABOUT UPDATE

AACI *Update* is an e-newsletter for the cancer center directors and key contacts at AACI member institutions as well as individuals interested in the cancer center-related activities of AACI. AACI *Update* reports on the progress of AACI initiatives along with other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

### SUBMISSIONS

AACI encourages member institutions to submit cancer center highlights to AACI *Update*. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to [aaciupdate@aaci-cancer.org](mailto:aaciupdate@aaci-cancer.org).

AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI *Update*, please send an e-mail to [aaciupdate@aaci-cancer.org](mailto:aaciupdate@aaci-cancer.org) with your name, title, and telephone number asking to be added to the AACI's distribution list. To unsubscribe, please send an email with "unsubscribe" in the subject line.

FIND US ON:



Southwestern Medical Center; Andrea Kruse, clinical trials network manager at Dana-Farber Cancer Institute, Harvard Medical School; and Cathy Hugney, RN, CCRP, regional oncology program manager at the Cleveland Clinic Taussig Cancer Institute, the Cleveland Clinic Foundation. To attend the webinar, please [register here](#). [more...](#)

## AACI Contributes to Report on Clinical Trial Enrollment

The American Cancer Society Cancer Action Network (ACS CAN) has issued a new report identifying barriers to enrolling cancer patients in clinical trials and proposing ways that they can be overcome. AACI Director of Programs **Janie Hofacker, RN, BSN, MS**, was a member of the steering committee that provided research, data, advice, and in some cases, text or edits, for the report. Ms. Hofacker represented AACI in a panel discussion, "Provider and Institution Barriers to Enrollment," during the report's release in April at the organization's annual National Policy Forum, held at the National Press Club, in Washington, DC. [more...](#)



## News from the Centers

[Awards & Honors](#) [Grants & Gifts](#) [Leadership Transitions](#) [Research Highlights](#) [Other News](#)

### Awards & Honors

#### Two Immunology Leaders Honored by Society for Thermal Medicine

**Roswell Park Comprehensive Cancer Center**


Two Roswell Park Comprehensive Cancer Center researchers who have focused their work around the impact of temperature on the immune system and its implications for cancer treatment were recently honored by the Society for Thermal Medicine (STM). Elizabeth Repasky, PhD was awarded the 2018 William C. Dewey Award and Sharon Evans, PhD received the J. Eugene Robinson Award at the STM's 2018 Annual Meeting in Tucson, Arizona, in May. [more...](#)



#### Strasberg Honored by Surgical Association

**Siteman Cancer Center**

Steven M. Strasberg, MD, the Pruet Professor of Surgery at Washington University School of Medicine in St. Louis, has received the 2018 Medallion for the Advancement of Surgical Care from the American Surgical Association. Dr. Strasberg treats patients at Siteman Cancer Center and Barnes-Jewish St. Louis Hospital. [more...](#)



#### Uzzo Recognized for Contributions to Urologic Oncology

**Fox Chase Cancer Center, Temple Health**

Robert G. Uzzo, MD, FACS, professor and chair of the Department of Surgical Oncology at Fox Chase Cancer Center, received the 2018 SUO Medal from the Society of Urologic Oncology (SUO) for his significant contributions to the field of urologic oncology. This prestigious award is presented to one member of SUO annually, and is among the organization's highest honors. [more...](#)



#### Weir Named Research Recipient of Global Health Repurposing Awards

**The University of Kansas Cancer Center**

Cures Within Reach, a leading global nonprofit focused on repurposing research as a fast track to impacting patients' lives, announced that Scott Weir, PharmD, PhD, is the recipient of the 2018 Janet Davison Rowley Patient Impact Research Award. Dr. Weir serves as director of the Institute for Advancing Medical Innovation (IAMI) and as associate director for translational research at The University of Kansas Cancer Center. [more...](#)



### **Tetzlaff Honored by the American Academy of Physician Assistants**

**Fox Chase Cancer Center, Temple Health**

Eric Tetzlaff, MHS, PA-C, DFAAPA, a physician assistant at Fox Chase Cancer Center, has received the AAPA 2018 Publishing Award. His paper, "National Study of Burnout and Career Satisfaction Among Physician Assistants in Oncology: Implications for Team-Based Care," appears in the *Journal of Oncology Practice*. [more...](#)

## **Grants & Gifts**

### **Major Donations To Help With NCI-Designation Efforts**

**University of Cincinnati Cancer Institute**


Over the past year, three major Cincinnati organizations—Fifth Third Foundation and Fifth Third Bank, Procter & Gamble and the Farmer Family Foundation—have donated a total of \$30 million (\$10 million each) to support the University of Cincinnati Cancer Institute in its quest for National Cancer Institute designation. These gifts will help to achieve this goal by assisting in the recruitment and hiring of researchers and clinicians dedicated to accelerating the progress of cancer research. [more...](#)



### **New Grant Funds Clinical Trial for Late-Stage Lung Cancer**

**UCLA Jonsson Comprehensive Cancer Center**

Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have been awarded a \$12 million grant from the California Institute for Regenerative Medicine (CIRM) to initiate a phase 1 clinical trial to test a novel cancer treatment for advanced-stage lung cancer. The treatment will combine the immunotherapy drug pembrolizumab with injections of the patient's own genetically modified immune cells directly into lung cancer tumors. Directed by Dr. Steven Dubinett, MD, the goal of the trial is to use this combined approach to activate a targeted and precise immune response against lung cancer. [more...](#)



### **McDonnell Team Awarded \$7 Million For Breast Cancer Study**

**Duke Cancer Institute**

A team of researchers led by Duke Cancer Institute scientist Donald McDonnell, PhD has been awarded a Breast Cancer Research Program Innovator Award, totaling \$7,368,485, by the United States Department of Defense Office of Congressionally Directed Medical Research Programs. The goal of the four-year translational project, "Cancer Cell Intrinsic and Extrinsic Actions of Steroid Hormones in Breast Tumors," is to develop strategies to improve the effectiveness of existing and emerging endocrine therapies taken to prevent breast cancer recurrence by women whose breast cancer is ER-positive (estrogen receptor-alpha). [more...](#)

### **\$5 Million Supports Innovative Breast Cancer Trial**

**Siteman Cancer Center**

A \$5 million grant from the Department of Defense will support research at Washington University School of Medicine in St. Louis aimed at improving breast cancer therapies. The study, which includes a clinical trial at Siteman Cancer Center at Barnes-Jewish Hospital and the School of Medicine, will focus on HER2-positive breast cancer. Such tumors are dotted with an overabundance of so-called HER2 receptors. [more...](#)

## **Leadership Transitions**

### **Berlin Assumes New VICC Leadership Post**

**Vanderbilt-Ingram Cancer Center**

Jordan Berlin, MD has been named associate director of clinical investigation strategy and shared resources at Vanderbilt-Ingram Cancer Center (VICC). In his new role he will chair the Resource Allocation Committee and continue as chair of the Clinical Trials Shared Resource



Steering Committee. Dr. Berlin is an Ingram Professor of Cancer Research, co-leader of the Gastrointestinal (GI) Cancer Research Program and director of the Phase 1 Clinical Trials Program at VICC. [more...](#)



### **Deputy Director for Research Administration Announced**

**UPMC Hillman Cancer Center**

Chad A. Ellis, PhD has been hired as the new deputy director for research administration at the UPMC Hillman Cancer Center in Pittsburgh. Dr. Ellis brings extensive knowledge and experience to Hillman, and over 13 years of a uniquely relevant track record to this critical senior leadership role. He most recently served as the associate director for administration and planning at UNC Lineberger Comprehensive Cancer in Chapel Hill, NC. Prior to that, he had served as the deputy director for research affairs at Yale Comprehensive Cancer Center. [more...](#)



### **New Medical Oncology Chair Leads Myeloid Malignancies Research**

**Dana-Farber Cancer Institute**

In the 17 years since he joined Dana-Farber as a clinical fellow in hematology-oncology, Benjamin Ebert, MD, PhD has made critical contributions to the understanding and treatment of hematologic disorders such as leukemia and myelodysplastic syndrome (MDS). Now, as newly appointed chair of the Institute's Department of Medical Oncology, Dr. Ebert directs more than 200 faculty members and more than 40 laboratories studying the causes of, and discovering new therapies for, a wide range of adult cancers. [more...](#)



### **UCSF Welcomes First Vice President/Chief Medical Officer for Cancer Services**

**UCSF Helen Diller Family Comprehensive Cancer Center**

Laura Crocitto, MD, MHA has been named UCSF's first vice president and chief medical officer for cancer services. An experienced urologic oncologist and physician executive, she joins the HDFCCC leadership team during an exciting period of growth, in advance of the anticipated opening of the Precision Cancer Medicine Building in 2019. Dr. Crocitto will help guide the leadership team in addressing quality and safety measures, better integration of disease site teams, common care delivery practices, aligning quality metrics with performance, and developing strategies for a growing regional network. [more...](#)



### **International Scientist is New Chief of Myeloma**

**Roswell Park Comprehensive Cancer Center**

Jens Hillengass, MD is the new Chief of Myeloma at Roswell Park Comprehensive Cancer Center. Prior to this, Dr. Hillengass served as deputy chief of the section of multiple myeloma at the University of Heidelberg in Germany. While there, he was responsible for the largest autologous stem-cell transplant program in that country, led the workgroup for hemato-oncological imaging at the German Cancer Research Center, and was an attending physician and associate professor. [more...](#)


### **Vice President of Cancer Services Named**

**WVU Cancer Institute**

Richard Funnell, MHA, FACHE, CMPE, has joined the WVU Cancer Institute as vice president of cancer services. Funnell comes to WVU Medicine from the University of Pennsylvania Health System, Penn Medicine, where he



served as chief administrative officer of the cancer service line and was responsible for the strategic direction and clinical operations of the Abramson Cancer Center. [more...](#)



### **Salama Named Director of Melanoma Program**

**Duke Cancer Institute**

April Salama, MD, previously interim director of Duke Cancer Institute's melanoma program, was recently named director of the program. Since assuming the role as interim director three years ago, Dr. Salama has advanced the melanoma program at Duke Cancer Institute. [more...](#)



### **Park Named to Breast Cancer Leadership Position**

**Vanderbilt-Ingram Cancer Center**

Breast cancer expert Ben Ho Park, MD, PhD, has been named co-leader of the breast cancer research program, director of Precision Oncology and associate director for translational research at Vanderbilt-Ingram Cancer Center. Dr. Park, who will assume his new post September 1, succeeds Carlos L. Arteaga, MD, who moved to the University of Texas Southwestern Medical Center as director of the Harold C. Simmons Comprehensive Cancer Center. [more...](#)



### **Schmidt to Join WVU Cancer Institute**

**WVU Cancer Institute**

WVU Medicine announced that Carl Schmidt, MD, a nationally-recognized surgical oncologist specializing in cancers of the liver, pancreas, and stomach, will join the WVU Cancer Institute in July. Dr. Schmidt will serve as chief of surgical oncology and surgeon in chief of the WVU Cancer Institute. He said his focus will be on clinical programs and education, while continuing to put out innovative research that will affect patient care. [more...](#)

## **Research Highlights**



### **Could Reading our Circadian Clocks According to DNA Repair Optimize Chemotherapy**

**UNC Lineberger Comprehensive Cancer Center**

UNC Lineberger scientists led by Aziz Sancar, MD, PhD analyzed whole-genome DNA repair in an animal over 24 hours to find which genes were repaired, where exactly, and when, laying the groundwork for a more precise use of anti-cancer drugs. Sancar's lab developed a way to measure DNA repair after cisplatin treatment over the course of a 24-hour circadian cycle throughout an entire genome of a mammal. They found the repair processes of transcribed strands tended to peak at pre-dawn or pre-dusk, depending on the gene. But repair of the non-transcribed strand tended to peak only at pre-dusk. Knowing how and when normal cells in various organs undergo DNA repair would help doctors understand the best times to administer drugs. [more...](#)



### **Trial to Determine Therapies for Eradication of Multiple Myeloma**

**UAB Comprehensive Cancer Center**

Researchers at the University of Alabama at Birmingham Division of Hematology and Oncology are leading and currently recruiting for a phase II clinical trial that intends to provide newly diagnosed multiple myeloma patients an innovative treatment plan. The hope is that the therapies will eradicate the disease in a significant proportion of patients and measure

disease response more accurately than ever before. Luciano Costa, MD, PhD is principal investigator. [more...](#)



### **Researchers Map Intricacies of Lung Cancer in One of Their Own** **Stanford Cancer Institute**

When James Spudich, PhD (at left in photo) was diagnosed with lung cancer, researchers had a rare and unexpected opportunity to study healthy and diseased human tissue at an unprecedented level of detail. Dr. Spudich shared his own tissue samples with Mark Krasnow, MD, PhD (also pictured) and other Stanford colleagues to help advance their work. [more...](#)



### **Under Certain Conditions, Bacterial Signals Set the Stage for Leukemia** **The University of Chicago Medicine Comprehensive Cancer Center**

A new study by researchers from the University of Chicago Medicine shows that bacterial signals are crucial to the development of a precursor condition to leukemia, which can be induced by disrupting the intestinal barrier or by introducing a bacterial infection. Bana Jabri, MD, PhD is senior author of the study. [more...](#)

### **Altered Immune Cells Clear Childhood Brain Tumor in Mice**


**Stanford Cancer Institute**

Engineered human immune cells can vanquish a deadly pediatric brain tumor in a mouse model, a study from the Stanford University School of Medicine has demonstrated. The study represents the first time a severe human brainstem tumor, diffuse intrinsic pontine glioma, has been eradicated in mice. [more...](#)

### **Brain Tumor Therapy is Going to the Dogs**

**UAB Comprehensive Cancer Center**

Dogs and humans are among the few species that spontaneously develop naturally occurring brain tumors. Those tumors have a lot in common, too, which has led scientists at the University of Alabama at Birmingham to wonder whether studying tumors in dogs will help treat humans, and whether studying tumors in humans will help treat man's best friend. [more...](#)



### **Trial to Test Experimental Immunotherapy in Breast Cancer Before Chemotherapy, Surgery**

**VCU Massey Cancer Center**

A phase 2 clinical trial at VCU Massey Cancer Center is testing the benefits of adding an experimental immunotherapy combination prior to standard chemotherapy and surgery for breast cancer patients. The trial was developed by Massey and is based on laboratory research led by Harry Bear, MD, PhD. [more...](#)

### **New 'Scoring' System Improves Survival Forecasting for Advanced Colorectal Cancer**

**Sidney Kimmel Comprehensive Cancer Center**

Georgios Margonis, MD, PhD and Matthew Weiss, MD report advances in efforts to improve the treatment and prognosis of colorectal cancers that have spread to the liver, including an improved preoperative disease scoring system, guidelines for surgeons excising liver metastases, and increased accuracy of postoperative prognoses. [more...](#)



### **Prolonged Exposure to Air Pollution Leads to Genetic Changes in Rat Brains, Study Finds**

**Samuel Oschin Comprehensive Cancer Institute**

Prolonged exposure to particulate matter in air pollution in the Los Angeles Basin triggered inflammation and the appearance of cancer-related genes in the brains of rats, a Cedars-Sinai study has found. While previous research has documented the association between air pollution and a variety of diseases, including cancer, the study found markers

indicating certain materials in coarse air pollution —nickel, in particular— may play a role in genetic changes related to disease development, said Julia Ljubimova, MD, PhD, lead author of the paper. [more...](#)

### **Improving Survival in Pancreatic Cancer with Platinum-Based Chemotherapy**

**Sidney Kimmel Comprehensive Cancer Center**

A small study of adults with the most common form of pancreatic cancer adds to evidence that patients with BRCA1 or BRCA2 gene mutations long linked to a high risk of breast cancer have poorer overall survival rates than those without the mutations. The study also found that those with BRCA1 or BRCA2 had better survival rates with platinum-based chemotherapy, compared with similar patients who received other drugs or no chemotherapy. [more...](#)



### **Preclinical Study Suggests ARID1a may be Useful Biomarker for Immunotherapy**

**University of Texas MD Anderson Cancer Center**

Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to immune checkpoint blockade therapies, according to researchers from The University of Texas MD Anderson Cancer Center. The preclinical study suggests that mutations in ARID1a could be beneficial in predicting immunotherapy success. Guang Peng, MD, PhD is senior author on the study. [more...](#)



### **Unlocking Cancer's Secrets Using the 'Social Networks' of Cells**

**The University of Arizona Cancer Center**

Megha Padi, PhD, director of the UA Cancer Center Bioinformatics Shared Resource, has developed a computer algorithm called ALPACA that reveals which gene networks are activated in a diseased cell - an approach that could lead to better treatments for various diseases. Cancer researchers usually focus on specific genes when comparing healthy cells to tumor cells, an approach that does not completely explain what occurs behind the scenes to cause cancer. [more...](#)

### **How Signals Get Inside Cancer Cells and Spur Aggressive Growth**

**University of Michigan Rogel Cancer Center**

The outside of a cancer cell is bombarded by signals. They come from the immune system, supporting tissues, and other structures. But how do those signals affect cancer? A new study provides a surprising model of the process by which those signals enter and influence the cell. The finding could open up a potential new avenue to pursue new therapies against cancer. [more...](#)

### **Understanding Genetic Test Results for Prostate Cancer**

**Sidney Kimmel Cancer Center at Thomas Jefferson University**

A recent report from the Genetic Evaluation of Men (GEM) study led by Sidney Kimmel Cancer Center (SKCC) at Jefferson Health researchers shows that while men who have inherited genetic mutations related to their prostate cancer are more likely to have a good understanding of general genetic test results, some men had confusion about a subcategory of genetic results - genetic variants of uncertain significance. [more...](#)

### **FDA Clears Phase 1 Trial in Graft-versus-Host Disease Patients**

**The University of Kansas Cancer Center**

The University of Kansas Medical Center has announced that the US Food and Drug Administration (FDA) has cleared it to begin a first-in-human clinical trial of MSCTC-0010 in patients with de novo high-risk acute or steroid-refractory acute graft-versus-host disease (HR/SR aGvHD). KU Medical Center is developing MSCTC-0010, a novel cellular therapy containing umbilical cord-derived Wharton's Jelly mesenchymal stem cells for the treatment of HR/SR aGvHD. [more...](#)



### **Immunotherapy Strategy For Ovarian Cancer Aims to Rewire A 'Kill Switch' to Ramp-Up Signal**

**Fred Hutchinson Cancer Research Center**

Kristin Anderson, PhD presented information at the American Association for Cancer Research's annual meeting about work that she and her colleagues are doing to overcome barriers that solid tumors construct to block immunotherapy. The researchers' latest strategy, developed and tested in ovarian cancer mouse and cell studies, involves a new hybrid protein that, when added to T-cell therapy, tells engineered immune cells to ramp up their activity in response to what is normally a death signal. [more...](#)

### **Study Shows How Glioblastomas Get a Leg Up**

**Fred Hutchinson Cancer Research Center**

As cancers develop, they accumulate a host of genetic alterations, sometimes acquiring extra copies of hundreds or thousands of genes. Researchers at Fred Hutch and the Dana-Farber Cancer Institute developed a computational method to sift important cancer-promoting genes from thousands of irrelevant ones. [more...](#)



### **Breast Cancer Places Greater Financial Burden on Black Women**

**UNC Lineberger Comprehensive Cancer Center**

Stephanie Wheeler, PhD and colleagues report that a survey of women diagnosed with breast cancer in North Carolina found 58 percent of black women reported a negative financial impact of cancer, compared with 39 percent of white women two years after diagnosis. Black women more often reported having a barrier to their care that caused them to delay or refuse recommended treatment because of cost. The researchers are studying how patients communicate about cancer costs and seek financial support. [more...](#)

### **3D Cancer Model to Speed New Treatments**

**University of Virginia Cancer Center**

A scientist at the University of Virginia School of Medicine, working with biotech company HemoShear Therapeutics, has created a 3D cancer model that can replicate the complex nature and behavior of a real tumor. The model will help researchers better understand the disease and accelerate the development of new and better treatments. [more...](#)

### **CAR-T Immunotherapy Eliminates Metastatic Colorectal Cancer in Mice**

**Sidney Kimmel Cancer Center at Thomas Jefferson University**

Researchers at the Sidney Kimmel Cancer Center at Jefferson Health have shown that CAR-T cell therapy successfully kills tumors and prevents metastases in mouse models of the disease. The work is the last step of pre-clinical testing prior to human clinical trials.

"Colorectal cancer rates are exceptionally high in our region, and advanced stage disease is difficult to treat. The concept of moving CAR-T cell therapy to colorectal cancer is a major breakthrough and could address a major unmet clinical need. We are optimistic about the pre-clinical results," said Karen Knudsen, PhD, director of the center. [more...](#)

### **Study Confirms Curable State Between Single and Widespread Cancers**

**The University of Chicago Medicine Comprehensive Cancer Center**

In 1995, two University of Chicago-based cancer specialists suggested there was an intermediate state—somewhere between curable localized cancers and lethal widespread disease—for patients with metastatic cancer. Twenty-three years later those physicians, Samuel Hellman, MD, and Ralph R. Weichselbaum, MD both still at the University of Chicago, have confirmed their hypothesis and for the first time have identified molecular patterns that can be used to predict which patients are most likely to benefit from surgery, leading to long-term survival. [more...](#)

### **Researchers Create Guide For Explorers of the Submicroscopic World Inside Us**



**University of Virginia Cancer Center**

University of Virginia researchers, led by Wladek Minor, PhD, have established new guidelines for scientists mapping out the body molecule by molecule to help us better understand how our cells use metals such as iron and magnesium to maintain good health. The guidelines ultimately will benefit the battle against diseases such as cancer, assist in the development of new drugs, and ensure scientific results are accurate and can be reproduced. [more...](#)

**Surveillance Intensity Not Linked With Earlier Detection of Recurrence or Improved Survival in Colorectal Cancer**

**University of Texas MD Anderson Cancer Center**

A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of post-treatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II or III colorectal cancer (CRC). The study is the largest of surveillance intensity in CRC ever conducted. [more...](#)

**The Physics of Rapidly Spreading Cancer**

**LIVESTRONG Cancer Institutes**

Scientists have recently discovered a method in cancer's madness. They've been perplexed by how cancer cells, growing alongside healthy cells, often spread much faster into surrounding tissue than randomness would dictate. It's as if cancerous cells are intentionally moving directly outward, invading healthy tissue. Now, a team of chemists and physicists from The University of Texas at Austin have used a computer simulation to explain, for the first time, the physics driving this motion. [more...](#)

**Neuroendocrine Tumor Clinical Data Published**

**UK Markey Cancer Center**

Entrinsic Health Solutions in partnership with the Markey Cancer Center have announced clinical data showing the anti-diarrheal efficacy of enterade®—a glucose-free, amino acid oral rehydration solution - in neuroendocrine tumor (NET) patients. The results are published online in the 2018 ASCO Annual Meeting Proceedings. [more...](#)

**Other News**

**Using Facebook to Help Young Adults Quit Smoking**

**UCSF Helen Diller Family Comprehensive Cancer Center**

A national clinical trial testing a smoking cessation intervention for young adults that was conducted entirely on Facebook has found that smokers are 2.5 times more likely to quit after three months with the Facebook-based treatment than if they were referred to an online quit-smoking program. It is the first study to test the effectiveness of a smoking intervention delivered entirely on Facebook and to also use biochemically-verified abstinence from smoking. [more...](#)

**Bowden Remembered as Gifted Scientist, Teacher, and Mentor**

**The University of Arizona Cancer Center**

George Timothy "Tim" Bowden, PhD, a professor emeritus at the University of Arizona Cancer Center and a founding member of the Cancer Biology Graduate Interdisciplinary Program, died May 15 after a lengthy battle with Parkinson's disease. [more...](#)

**Job Opportunities**

**Senior Biostatistician**

**University of Illinois Cancer Center** [more...](#)

**Regulatory Specialist - Cancer Center (Clinical Trials Office)**

**University of Illinois Cancer Center** [more...](#)

**Associate Professor or Professor**

**Stony Brook University Cancer Center** [more...](#)

**Clinical Investigator**

**The University of Kansas Cancer Center** [more...](#)

**Clinical Research Educator - Hem-Onc Clinical Trials**

**Penn State Cancer Institute** [more...](#)

**Manager of Clinical Research Operations - Hem-Onc Clinical Trials**

**Penn State Cancer Institute** [more...](#)

**Clinical Research Coordinator**

**Moffitt Cancer Center** [more...](#)

**Associate Director, Administration**

**University of Arizona Cancer Center** [more...](#)

## Meeting Announcements

### **The Noreen O'Neill Melanoma Research Symposium**

On Tuesday, June 26, The Wistar Institute will host a free scientific symposium, "The Noreen O'Neill Melanoma Research Symposium - Host Response in Melanoma," from 9:00 am - 4:30 pm.

The past decade has seen tremendous advances in the treatment of melanoma with next-generation approaches like targeted therapies, immunotherapies, and combination therapies that have changed the disease outcome for many patients. Despite the success of these varied strategies, the onset of drug resistance, or failure to respond to therapies at all, remains a problem for the majority of patients. How the host and tumor microenvironment play a role in the success or failure of these therapies is an important area of study.

Please join us and help spread the word! Registration is free, but required.

[wistar.org/melanoma2018](http://wistar.org/melanoma2018)

### **10th Annual AACI Clinical Research Initiative Meeting**

Register today: [aaci-cancer.org/crimeeting](http://aaci-cancer.org/crimeeting)

July 11-12, 2018

Loews Chicago O'Hare Hotel

Rosemont, IL

### **2018 Pan Pacific Lymphoma Conference**

July 16-20

Hyatt Regency Maui Resort & Spa

Maui, Hawaii

Join us for a five-day comprehensive educational conference with expert faculty from around the globe presenting the most up-to-date clinical advances in lymphoma and transplantation.

Registration deadline is June 22.

[unmc.edu/panpacificlymphoma](http://unmc.edu/panpacificlymphoma)

### **Multidisciplinary Approaches to Cancer Symposium**

September 20-23, 2018

Loews Coronado Bay Resort

4000 Coronado Bay Road

Coronado, CA 92118

[cme.cityofhope.org/eventinfo\\_9171](http://cme.cityofhope.org/eventinfo_9171)

### **ASCO Research Community Forum 2018 Annual Meeting**

September 23-24, 2018

DC Metro Area (Alexandria, VA)

This year's ASCO Research Community Forum (RCF) Annual Meeting will be held on September 23-24, 2018 at ASCO headquarters just outside Washington, DC. The meeting will feature a networking event, training workshop, general sessions, and discussions that provide concrete strategies to overcome common challenges associated with conducting clinical trials. Register today, space is limited.

For more information visit: [www.asco.org/research-progress](http://www.asco.org/research-progress)

### **Frontiers in Basic Immunology: 2018**

September 27-28, 2018

Masur and Lipsett Auditorium

Bldg. 10, NIH

Bethesda, MD

The Center for Cancer Research at the National Cancer Institute is hosting a two-day national symposium entitled "Frontiers in Basic Immunology: 2018." The program includes recent advances in the field and should be an exciting forum for discussion and debate on the current understanding of basic immunological mechanisms.

[ncifrederick.cancer.gov](http://ncifrederick.cancer.gov)

### **2018 AACI/CCAF Annual Meeting**

Register today: [aaci-cancer.org/annual\\_meeting](http://aaci-cancer.org/annual_meeting)

September 30-October 2, 2018

Loews Chicago Downtown Hotel

Chicago, IL

### **Neoplastic Hematopathology Update**

November 8-10, 2018

The Waterfront Beach Resort, A Hilton Hotel

[cme.cityofhope.org/eventinfo\\_9520](http://cme.cityofhope.org/eventinfo_9520)